Avidity Biosciences(RNA) - 2024 Q1 - Quarterly Results

Exhibit 99.1 Avidity Biosciences Reports First Quarter 2024 Financial Results and Recent Highlights Presented positive long-term del-desiran data from MARINA-OLE™ showing reversal of disease progression in people living with myotonic dystrophy type 1 across multiple endpoints; same key endpoints, with vHOT as primary, agreed for phase 3 HARBOR trial Cash position of $915 million at the end of Q124 following successful private placement SAN DIEGO, May 9, 2024 /PRNewswire/-- Avidity Biosciences, Inc. (Nasdaq: ...